Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ataru Inagaki

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
BMC Psychiatry|December 20, 2013
Cost of anxiety disorders in Japan in 2008: a prevalence-based approachMitsuhiro Sado, Sayuri Takechi, Ataru Inagaki, et al.
BMC Medical Research Methodology|April 30, 2002
Are the cochrane group registers comprehensive? A case study of Japanese psychiatry trialsToshi A Furukawa, Toshiya Inada, Clive E Adams, et al.
BMC Psychiatry|April 9, 2014
Study protocol: safety correction of high dose antipsychotic polypharmacy in JapanTsuruhei Sukegawa, Ataru Inagaki, Yoshio Yamanouchi, et al.
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|November 4, 2015
[Individually Safe and Realistic Correction of Antipsychotic Polypharmacy and High-dose Regimens in Japanese Patients with Chronic Schizophrenia: The SCAP method]Yoshio Yamanouchi, Tsuruhei Sukegawa, Ataru Inagaki, et al.
The International Journal of Neuropsychopharmacology|December 19, 2014
Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose methodYoshio Yamanouchi, Tsuruhei Sukegawa, Ataru Inagaki, et al.
Neuropsychiatric Disease and Treatment|June 21, 2013
The cost of schizophrenia in JapanMitsuhiro Sado, Ataru Inagaki, Akihiro Koreki, et al.
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|January 26, 2013
[Survey on the actual condition of psychiatrists and psychiatric services in Japan. (Part 1): Basic data on number and distribution of psychiatrists]Masafumi Mizuno, Ataru Inagaki, Shuichiro Fujiwara, et al.
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|January 26, 2013
[Survey on the actual condition of psychiatrists and psychiatric services in Japan. (Part 2): Change in geographical working area and setting of each psychiatrist]Ataru Inagaki, Masafumi Mizuno, Shuichiro Fujiwara, et al.
Asian Journal of Psychiatry|March 26, 2025
Budget impact analysis of long-acting injections for the treatment of Schizophrenia in JapanMami Kasahara-Kiritani, Chu-Chu Sheng, Nan Li, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|July 2, 2008
Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in JapanHiroyuki Uchida, Takefumi Suzuki, David C Mamo, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
BMC Psychiatry|December 20, 2013
Cost of anxiety disorders in Japan in 2008: a prevalence-based approachMitsuhiro Sado, Sayuri Takechi, Ataru Inagaki, et al.
BMC Medical Research Methodology|April 30, 2002
Are the cochrane group registers comprehensive? A case study of Japanese psychiatry trialsToshi A Furukawa, Toshiya Inada, Clive E Adams, et al.
BMC Psychiatry|April 9, 2014
Study protocol: safety correction of high dose antipsychotic polypharmacy in JapanTsuruhei Sukegawa, Ataru Inagaki, Yoshio Yamanouchi, et al.
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|November 4, 2015
[Individually Safe and Realistic Correction of Antipsychotic Polypharmacy and High-dose Regimens in Japanese Patients with Chronic Schizophrenia: The SCAP method]Yoshio Yamanouchi, Tsuruhei Sukegawa, Ataru Inagaki, et al.
The International Journal of Neuropsychopharmacology|December 19, 2014
Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose methodYoshio Yamanouchi, Tsuruhei Sukegawa, Ataru Inagaki, et al.
Neuropsychiatric Disease and Treatment|June 21, 2013
The cost of schizophrenia in JapanMitsuhiro Sado, Ataru Inagaki, Akihiro Koreki, et al.
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|January 26, 2013
[Survey on the actual condition of psychiatrists and psychiatric services in Japan. (Part 1): Basic data on number and distribution of psychiatrists]Masafumi Mizuno, Ataru Inagaki, Shuichiro Fujiwara, et al.
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|January 26, 2013
[Survey on the actual condition of psychiatrists and psychiatric services in Japan. (Part 2): Change in geographical working area and setting of each psychiatrist]Ataru Inagaki, Masafumi Mizuno, Shuichiro Fujiwara, et al.
Asian Journal of Psychiatry|March 26, 2025
Budget impact analysis of long-acting injections for the treatment of Schizophrenia in JapanMami Kasahara-Kiritani, Chu-Chu Sheng, Nan Li, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|July 2, 2008
Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in JapanHiroyuki Uchida, Takefumi Suzuki, David C Mamo, et al.
Pageof 3